MIM
OBIO icon

Monashee Investment Management’s Orchestra BioMed OBIO Stock Holding History

Monashee Investment Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$1.28M – 415
2020
Q4 		$1.28M Hold
100,000
– – 0.17% 144
2020
Q3 		$1.1M Buy
+100,000
New +$1.12M 0.24% 86

Other funds holding OBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return

Monashee Investment Management's OBIO Position: Q1 2021 in Review

Monashee Investment Management sold out of Orchestra BioMed (OBIO) in Q1 2021, closing a stake of 100,000 shares — an estimated $1.28M sold.

Monashee Investment Management first reported a position in OBIO in Q3 2020 and held it in 2 quarters. The position peaked at $1.28M in Q4 2020. 46 funds tracked by Wall St. Rank hold OBIO as of Q1 2021.

  • Monashee Investment Management reported no remaining Orchestra BioMed position as of Q1 2021 after selling out during the quarter.
  • Monashee Investment Management sold 100,000 Orchestra BioMed shares in Q1 2021, an estimated $1.28M.
  • Monashee Investment Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 2 quarters.
  • Monashee Investment Management's Orchestra BioMed position peaked at $1.28M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2021.

Based on Monashee Investment Management's 13F filing for Q1 2021, filed 14 May 2021.